Beruflich Dokumente
Kultur Dokumente
Doi: 10.1111/j.1742-7843.2008.00321.x
Journal compilation 2008 Nordic Pharmacological Society. Basic & Clinical Pharmacology & Toxicology, 103, 560568
561
Results
Evaluation of the characteristics of streptozotocin-induced
and streptozotocin-nicotinamide-induced diabetic rats.
Table 1 shows the main metabolic parameters of rats
established 1 week after the administration of streptozotocin
alone or streptozotocin and several doses of nicotinamide.
Compared to the normal rats, streptozotocin-induced diabetic
rats showed a marked increase in plasma glucose levels and
562
Body weight, plasma glucose and insulin levels, and pancreatic insulin content in the normal, streptozotocin (STZ)-induced and streptozotocinnicotinamide (STZ-NA)-induced diabetic rats.
STZ + NA
Normal
Body weight (g)
Fasting plasma glucose (mg/dl)
Non-fasting plasma glucose (mg/dl)
Fasting plasma insulin (ng/ml)
Non-fasting plasma insulin (ng/ml)
Pancreatic insulin content
(ng/mg pancreas)
STZ
50 mg/kg
1
100 mg/kg
150 mg/kg
200 mg/kg
308 8
94.6 5.3
124 2
0.55 0.04
1.85 0.08
243 4
249 171
643 121
0.27 0.031
0.54 0.071
264 13
179 151
386 181
0.50 0.06
0.91 0.091
295 6
125 8
206 31
0.52 0.05
1.42 0.081
302 10
117 5
166 31
0.61 0.05
1.66 0.11
313 4
102 8
137 10
0.70 0.09
1.85 0.15
99.5 7.8
9.7 0.91
30.9 7.01
53.3 2.01
76.7 8.7
91.3 8.3
Data are expressed as the mean S.E.M. from five animals in each group. The significance of differences between the normal and diabetic
groups was assessed using Dunnetts multiple range test (1P < 0.05 versus the normal group).
563
Fig. 1. (A) Plasma glucose and (B) insulin levels during an oral glucose tolerance test in the normal, streptozotocin (STZ)- and
streptozotocin-nicotinamide (STZ-NA)-induced diabetic rats. Values are expressed as the mean S.E.M. from five animals in each group.
The significance of differences between the normal and diabetic groups was assessed using Dunnetts multiple range test (*P < 0.05 versus the
normal group).
564
Fig. 2. Hypoglycaemic effect of antidiabetic drugs on glucosetolerance in mildly diabetic rats during the liquid meal tolerance test (LMTT).
Effect of (A) voglibose, (B) metformin, (C) glibendamide, (D) sitagliptin and (E) insulin on plasma glucose levels during the LMTT. (F)
Plasma glucose AUC during the LMTT. Values are expressed as the mean S.E.M. from four animals in each group. The significance of
differences between the normal and diabetic vehicle group was assessed using Students t-test (*P < 0.05 versus the normal group). The
significance of differences between the vehicle and each antidiabetic drug-treated groups was assessed using Dunnetts multiple range test
(P < 0.05 versus the vehicle group).
565
Fig. 3. Effect of antidiabetic drugs on plasma insulin and GLP-1 levels in mildly diabetic rats during the liquid meal tolerance test (LMTT).
(A) Plasma insulin and (B) GLP-1 levels under basal (fasted) conditions and 15 min. after liquid meal loading. Values are expressed as the mean
S.E.M. from four animals in each group. The significance of differences between the normal and diabetic vehicle groups was assessed using
Students t-test (*P < 0.05 versus the normal group). The significance of differences between the vehicle and antidiabetic drug-treated groups was
assessed using Dunnetts multiple range test (P < 0.05 versus the vehicle group).
566
Fig. 4. Hypoglycemic effect of antidiabetic drugs on glucose tolerance in severely diabetic rats during the liquid meal tolerance test (LMTT).
Effect of (A) voglibose, (B) metformin, (C) glibenclamide, (D) sitagliptin and (E) insulin on plasma glucose levels during the LMTT. (F)
Plasma glucose AUC during the LMTT. Values are expressed as the mean S.E.M. from four animals in each group. The significance of
differences between the normal and diabetic vehicle groups was assessed using Students t-test (*P < 0.05 versus the normal group). The
significance of differences between the vehicle and each antidiabetic drug-treated groups was assessed using Dunnetts multiple range test
(P < 0.05 versus the vehicle group).
567
Fig. 5. Effect of antidiabetic drugs on plasma insulin and GLP-1 levels in severely diabetic rats during the liquid meal tolerance test (LMTT).
(A) Plasma insulin and (B) GLP-1 levels under basal (fasted) conditions and 15 min. after liquid meal loading. Values are expressed as the
mean S.E.M. from four animals in each group. The significance of differences between the normal and diabetic vehicle groups was assessed
using Students t-test (*P < 0.05 versus the normal group). The significance of differences between the vehicle and antidiabetic drug-treated groups
was assessed using Dunnetts multiple range test (P < 0.05 versus the vehicle group).
References
1 Srinivasan K, Ramarao P. Animal models in type 2 diabetes
research: an overview. Indian J Med Res 2007;125:45172.
2 Ladriere L, Malaisse-Lagae F, Fuhlendorff J, Malaisse WJ.
Repaglinide, glibenclamide and glimepiride administration to
normal and hereditarily diabetic rats. Eur J Pharmacol
1997;335:22734.
3 Efanov AM, Appelskog IB, Abdel-Halim SM, Khan A, Branstrom
R, Larsson O et al. Insulinotropic activity of the imidazoline
derivative RX871024 in the diabetic GK rat. Am J Physiol
Endocrinol Metab 2002;282:E117 24.
4 Portha B, Serradas P. Improvement in glucose-induced insulin
secretion in diabetic rats after long-term gliclazide treatment:
a comparative study using different models of non-insulindependent diabetes mellitus induced by neonatal streptozotocin.
Am J Med 1991;90:S15 S21.
5 Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition
of dipeptidyl peptidase IV with NVP-DPP728 increases plasma
GLP-1 (7-36 amide) concentrations and improves oral glucose
tolerance in obese Zucker rats. Diabetologia 1999;42:1324 31.
6 Mine T, Miura K, Kitahara Y, Okano A, Kawamori R.
Nateglinide suppresses postprandial hypertriglyceridemia in
Zucker fatty rats and Goto-Kakizaki rats: comparison with
voglibose and glibenclamide. Biol Pharma Bull 2002;25:14126.
7 Farrar NS, Chambers NJ, Carlsson AR, Denyer G, Johnston
GA. Effect of a series of novel sulphonylthioureas on glucose
tolerance in the obese fa/fa Zucker rat. Clin Exp Pharmacol
Physiol 2001;28:38691.
8 Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport
and cytotoxicity. Specific enhancement in GLUT2-expressing cells.
Diabetes 1994;43:1326 33.
9 Turk J, Corbett JA, Ramanadham S, Bohrer A, McDaniel
ML. Biochemical evidence for nitric oxide formation from
streptozotocin in isolated pancreatic islets. Biochem Biophys
Res Commun 1993;197:145864.
568